Cost effectiveness of palivizumab in Spain: an analysis using observational data
Open Access
- 5 December 2009
- journal article
- research article
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 11 (1) , 105-115
Abstract
Objectives To assess the cost effectiveness of palivizumab for prevention of severe respiratory syncytial virus (RSV) disease in high-risk infants in Spain, incorporating country-specific observational hospitalisation data. Methods An existing decision tree model, designed using data from a large international clinical trial of palivizumab versus no prophylaxis, was updated to include Spanish observational hospitalisation data. The analysis was performed for preterm children born at or before 32 weeks gestational age, who are at high risk of developing severe RSV disease requiring hospitalisation. Data sources included published literature, official price/tariff lists and national population statistics. The primary perspective of the study was that of the Spanish National Health Service in 2006. Results The base-case analysis included the direct medical costs associated with palivizumab prophylaxis and hospital care for RSV infections. Use of palivizumab produces an undiscounted incremental cost-effectiveness ratio (ICER) of €6,142 per quality-adjusted life-year (QALY), and a discounted ICER of €12,814/QALY. Conclusion Palivizumab provides a cost-effective method of prophylaxis against severe RSV disease requiring hospitalisation among preterm infants in Spain.Keywords
This publication has 24 references indexed in Scilit:
- Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk ChildrenPharmacoEconomics, 2007
- La eficiencia (coste-efectividad) de palivizumab como profilaxis para la infección por virus respiratorio sincitial en prematuros de 32-35 semanas en EspañaAnales de Pediatría, 2006
- Thresholds in Cost-Effectiveness Analysis—More of the StoryValue in Health, 2005
- Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart diseaseThe Journal of Pediatrics, 2003
- Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infantsThe Pediatric Infectious Disease Journal, 2003
- Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infectionArchives of Disease in Childhood, 2001
- Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective studyThe Pediatric Infectious Disease Journal, 2000
- Respiratory syncytial virus infectionThe Lancet, 1999
- Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk InfantsPediatrics, 1998
- The Selection of Data Sources For Use in Modelling StudiesPharmacoEconomics, 1998